Ellipses in-licenses first-in-class B7H3 antibody drug conjugate from China

Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative ...

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza ...
Business Insider

Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the ...

SOUTH SAN FRANCISCO, Calif., June 15, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of ...
News-Medical.Net

Complete ADC conjugation in just 3 hours: Speed without compromise

ADC conjugation, redefined. Explore a rapid 3-hour workflow that delivers precise, controlled antibody-drug conjugates for ...
Yahoo Finance

Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors

Kyung-Ah Kim, President & CEO of Samsung Bioepis (left) and Zhaoyuan ‘Tony’ Chen, Founder and CEO of Phrontline Biopharma (right) have signed a global strategic partnership agreement to advance ...
Seeking Alpha

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability ...
Business Wire

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

LAUSANNE, Switzerland & SUWON-SI GYEONGGI-DO, South Korea--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s ...
NBC4 Columbus

GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate

SUZHOU, China, April 18, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an ...
Morningstar

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage ...
Business Wire

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, and Duality Biotherapeutics ...